Viking Therapeutics Inc. (VKTX)
Viking Therapeutics Statistics
Share Statistics
Viking Therapeutics has 112.29M shares outstanding. The number of shares has increased by 1.8% in one year.
| Shares Outstanding | 112.29M |
| Shares Change (YoY) | 1.8% |
| Shares Change (QoQ) | 0.73% |
| Owned by Institutions (%) | 73.86% |
| Shares Floating | 108.97M |
| Failed to Deliver (FTD) Shares | 12.37K |
| FTD / Avg. Volume | 0.26% |
Short Selling Information
The latest short interest is 25.62M, so 22.81% of the outstanding shares have been sold short.
| Short Interest | 25.62M |
| Short % of Shares Out | 22.81% |
| Short % of Float | 27.38% |
| Short Ratio (days to cover) | 8.53 |
Valuation Ratios
The PE ratio is -39.9 and the forward PE ratio is -11.08. Viking Therapeutics's PEG ratio is -3.63.
| PE Ratio | -39.9 |
| Forward PE | -11.08 |
| PS Ratio | 0 |
| Forward PS | 3.2 |
| PB Ratio | 4.98 |
| P/FCF Ratio | -49.98 |
| PEG Ratio | -3.63 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Viking Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 33.09, with a Debt / Equity ratio of 0.
| Current Ratio | 33.09 |
| Quick Ratio | 33.09 |
| Debt / Equity | 0 |
| Debt / EBITDA | -0.01 |
| Debt / FCF | -0.01 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $0 |
| Profits Per Employee | $-3.05M |
| Employee Count | 36 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -62.25% in the last 52 weeks. The beta is 0.83, so Viking Therapeutics's price volatility has been higher than the market average.
| Beta | 0.83 |
| 52-Week Price Change | -62.25% |
| 50-Day Moving Average | 27.47 |
| 200-Day Moving Average | 47.72 |
| Relative Strength Index (RSI) | 46.06 |
| Average Volume (20 Days) | 4.71M |
Income Statement
| Revenue | n/a |
| Gross Profit | 0 |
| Operating Income | -150.92M |
| Net Income | -109.96M |
| EBITDA | -150.92M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -1.01 |
Balance Sheet
The company has 26.68M in cash and 1.12M in debt, giving a net cash position of 25.56M.
| Cash & Cash Equivalents | 26.68M |
| Total Debt | 1.12M |
| Net Cash | 25.56M |
| Retained Earnings | -487.91M |
| Total Assets | 908.32M |
| Working Capital | 879.8M |
Cash Flow
In the last 12 months, operating cash flow was -87.79M and capital expenditures 0, giving a free cash flow of -87.79M.
| Operating Cash Flow | -87.79M |
| Capital Expenditures | 0 |
| Free Cash Flow | -87.79M |
| FCF Per Share | -0.81 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
VKTX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for VKTX is $99, which is 313.5% higher than the current price. The consensus rating is "Buy".
| Price Target | $99 |
| Price Target Difference | 313.5% |
| Analyst Consensus | Buy |
| Analyst Count | 12 |
Scores
| Altman Z-Score | 58.89 |
| Piotroski F-Score | 2 |